e-learning
resources
Virtual 2021
05.09.2021
Severe asthma: evaluation using patient-reported outcome measures (PROMs) and biomarkers, comorbidities and treatments
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Eosinophilic refractory inflammation in OCS-dependent severe asthma
V. Carriero (Orbassano, Italy), F. Bertolini (Orbasssano, Italy), E. Arrigo (Orbasssano, Italy), F. Ricciardolo (Orbassano, Italy)
Source:
Virtual Congress 2021 – Severe asthma: evaluation using patient-reported outcome measures (PROMs) and biomarkers, comorbidities and treatments
Session:
Severe asthma: evaluation using patient-reported outcome measures (PROMs) and biomarkers, comorbidities and treatments
Session type:
E-poster
Number:
1103
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
V. Carriero (Orbassano, Italy), F. Bertolini (Orbasssano, Italy), E. Arrigo (Orbasssano, Italy), F. Ricciardolo (Orbassano, Italy). Eosinophilic refractory inflammation in OCS-dependent severe asthma. 1103
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Respiratory sequelae of preterm birth across the life span
Related content which might interest you:
Late-onset persistent eosinophilic severe asthma
Source: International Congress 2015 – Severe asthma phenotyping
Year: 2015
Eosinophilic inflammation and asthma control
Source: Annual Congress 2009 - Inflammation and airways
Year: 2009
Benralizumab for severe asthma associated with extra-airway eosinophilic diseases
Source: Virtual Congress 2020 – Monoclonal antibodies in asthma
Year: 2020
Eosinophilic asthma
Source: Eur Respir Monogr 2022; 95: 73-99
Year: 2022
Eosinophilic airway inflammation in COPD and asthma
Source: Annual Congress 2008 - Invasive and noninvasive measurements of lung inflammation
Year: 2008
Severe therapy-resistant asthma
Source: International Congress 2016 – PG8 Paediatric asthma
Year: 2016
Neutrophilic severe asthma
Source: International Congress 2015 – Severe asthma phenotyping
Year: 2015
Mepolizumab in real-life treatment of severe eosinophilic asthma
Source: Virtual Congress 2020 – Monoclonal antibodies in asthma
Year: 2020
Asthma exacerbations and eosinophilic inflammation 6 months after treatment with mepolizumab in refractory eosinophilic asthma
Source: Annual Congress 2009 - Towards improving asthma control
Year: 2009
Effects of omalizumab on markers of eosinophilic inflammation in patients with severe allergic asthma
Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD
Year: 2011
Effect of anti-IL5 treatment on symptoms of chronic rhinosinusitis, otitis and hearing loss in patients with severe eosinophilic asthma
Source: International Congress 2019 – Clinical approach to asthma management
Year: 2019
Manifestation of idiopathic chronic eosinophilic pneumonia
Source: Annual Congress 2009 - Clinical aspects of diffuse parenchymal lung disease
Year: 2009
Pathophysiology of non-eosinophilic severe asthma
Source: International Congress 2017 – Pathophysiology and emerging therapies for severe asthma
Year: 2017
Idiopathic chronic eosinophilic pneumonia and asthma: how do they influence each other?
Source: Eur Respir J 2003; 22: 8-13
Year: 2003
Severe asthma
Source: ISSN=ISSN 1810-6838, ISBN=, page=128
Year: 2006
Severe asthma
Source: ERS Course 2019 - Masterclass in airways disease 2019
Year: 2019
Severe asthma
Source: ERS Lung Science Conference 2016
Year: 2016
Severe asthma
Source: International Congress 2014 – ERS/CTS China Day: advances in asthma and COPD
Year: 2014
Rapid Benralizumab effectiveness in patients with severe eosinophilic asthma and bronchiectasis
Source: Virtual Congress 2020 – Monoclonal antibodies in asthma
Year: 2020
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept